CCM: Chongqing Lummy withdraws registration application for glutamine capsule

Keyword:
Publish time: 30th June, 2016      Source: CCM
Information collection and data processing:  CCM     For more information, please contact us
On 31 May, 2016, Chongqing Lummy Pharmaceutical Co., Ltd. (Chongqing Lummy), a domestic listed pharmaceutical enterprise (stock code: 300006), announced that it had applied for the withdrawal of glutamine capsule registration and got approved by the China Food and Drug Administration (CFDA).

  
"We made this decision after deliberate consideration, taking into account the company's reality and the latest policies released by the CFDA," said Chongqing Lummy.

  
Early in Jan. 2009, the company had applied for the clinical trial on glutamine capsule (0.25 g/capsule) and got accepted (Acceptance No.: CYHS0900040). This capsule is an amino acid drug used for the treatment of gastric and duodenal ulcers.

  \

  

   Glutamine, one of the most common amino acids in daily life, plays a vital role in adjusting protein synthesis, restraining protein degradation, promoting cell growth, activating immune system and increasing growth hormone. Thus, it is widely applied in fields of food, pharmaceuticals, feed and so on. For instance,

  
        
  •       Japan: L-glutamine   was launched as an anti-ulcer drug in 1979     
  •     
  •       The US: L-glutamine   is largely used in healthcare products treating gastric ulcer and   nutrition supplements for athletes     
  •     
  •       German: L-glutamine   has been recorded onto pharmacopeia as a drug for gastritis, gastric and   duodenal ulcers     
  •   

  
So far, several Chinese enterprises have been got approvals for production and import of L- glutamine API, tablets and capsules. Leading glutamine preparation producers include YaoPharma Co., Ltd., Jiangsu Shenhua Pharmaceutical Co., Ltd. and Shandong Lukang Pharmaceutical Group Co., Ltd.

   

  Chongqing Lummy, founded in 1999, is a high-tech pharmaceutical enterprise devoted to the R&D, production and sale of anti-infection and specialized drugs. It is one of the domestic producers boasting the most complete injection formulations, such as small & large volume injections, powder injections and freeze-dried powder injections. Notably, in Q1 2016, the company reported a large YoY increase of 239.66% in net profit.

  

  *This article comes from Amino Acid China News 1606, CCM

  

  

  

  

  About CCM:

  CCM is the leading market intelligence provider for China's agriculture, chemicals, food & ingredients and life science markets. Founded in 2001, CCM offers a range of data and content solutions, from price and trade data to industry newsletters and customized market research reports. Our clients include Monsanto, DuPont, Shell, Bayer, and Syngenta. CCM is a brand of Kcomber Inc.

   

  For more information about CCM, please visit www.cnchemicals.com or get in touch with us directly by emailing econtact@cnchemicals.com  or calling +86-20-37616606.

  

  Tag: glutamine